Valuation : Indivior Pharmaceuticals, Inc.

Market Cap 4.12B 3.54B 3.33B 3.04B 5.71B 392B 5.75B 39.42B 15.34B 199B 15.45B 15.12B 657B P/E 2026 *
9.4x
P/E 2027 * 8.52x
Enterprise Value 4.1B 3.53B 3.32B 3.03B 5.69B 390B 5.73B 39.3B 15.29B 198B 15.4B 15.07B 655B EV / Sales 2026 *
3.08x
EV / Sales 2027 * 2.53x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
1 week 29.8
Extreme 29.8
31
1 month 29.8
Extreme 29.8
34.2
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%-6.79% - - 4.12B
-1.52%-7.86%+57.90%+111.09% 1,047B
-0.82%-1.62%+50.05%+62.37% 646B
+0.37%-3.22%+21.87%+72.88% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.45%-0.27%+29.84%+91.34% 181B
Average -0.70%-2.68%+27.56%+48.48% 406.59B
Weighted average by Cap. -0.77%-3.46%+36.91%+64.88%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.08B 983M 1.85B 127B 1.86B 12.76B 4.96B 64.27B 5B 4.89B 213B 1.4B 1.2B 1.13B 1.03B 1.94B 133B 1.95B 13.41B 5.22B 67.53B 5.25B 5.14B 224B
Net income 474M 408M 383M 350M 658M 45.13B 662M 4.54B 1.77B 22.88B 1.78B 1.74B 75.77B 530M 456M 428M 391M 735M 50.43B 740M 5.08B 1.98B 25.57B 1.99B 1.95B 84.67B
Net Debt -12.5M -10.76M -10.11M -9.22M -17.33M -1.19B -17.45M -120M -46.59M -603M -46.93M -45.91M -2B -570M -491M -461M -421M -790M -54.23B -796M -5.46B -2.12B -27.5B -2.14B -2.09B -91.06B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Date Price Change
26-08-31 29.80 -1.32%
26-08-28 €30.20 -1.31%
26-08-27 €30.60 -1.29%
26-08-26 €31.00 0.00%
26-08-25 €31.00 -1.90%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.87USD
Average target price
49.00USD
Spread / Average Target
+40.52%

Quarterly revenue - Rate of surprise